23
Dec
2005
The new 25,000 square foot Bioscience East building at Fitzsimons signed its first tenant, DMI BioSciences, Inc.. DMI will occupy 15,000 sq. ft. of East on 1 May 2006. With two ongoing Phase II clinical trials DMI is among the more advanced companies residing in the bioscience park campus. DMI is a privately-held biopharmaceutical company [...]
15
Dec
2005
Today GlobeImmune finished packing and said good bye to the Fitzsimons Redevelopment Authority. Early pre-clinical success, human Phase I clinical trials, multiple rounds of capital raising and hiring have culminated in the need for additional space that Fitzsimons, in its current state, was unable to provide to the accelerating start-up. Another way to look at [...]
12
Dec
2005
Myogen announced today that Ambrisentan®, for pulmonary arterial hypertension, met the primary efficacy endpoint and several strategic secondary endpoints in this first Phase III trial. Results are expected shortly, in 1Q06, on an additional Phase III study. To date Ambrisentan® has demonstrated: • Improvement in exercise capacity• Improvement in time to clinical worsening• An apparent [...]
10
Dec
2005
CBSA Increases Horsepower
Posted in My Rants
Congratulations to Chris Shapard, former director of biosciences and emerging technologies for the Colorado Office of Economic Development and International Trade, who is now joining the Colorado Bioscience Association to lead their marketing and communication endeavors. We look forward to her efforts to make BioWest and the Bioscience Colorado Magazine bigger and better.
02
Dec
2005
The Colorado State University broke ground on a new $22 million bio-hazard research laboratory. Fort Collins is already home to the Center for Disease Control Vector-Borne Infectious Disease Laboratory. These two facilities now function to anchor a cluster for the study of bioterror and infectious disease causing agents and organisms. Yet another feather in the [...]
Life Science Deal Flow PARTNERS
-
